Peptides

Tesamorelin

A modified GHRH peptide studied in enzyme-degradation and analytical comparisons.

Amount

$120

Per unit

This amount is currently unavailable.

For in vitro laboratory research only. Not for human or veterinary use, or as a dietary supplement.

View Certificate of Analysis

Research profile

Scientific background

Preclinical studies

Tesamorelin, also designated TH9507, is a modified growth hormone-releasing hormone analog. The cited nonclinical paper compares peptide degradation in defined plasma systems and examines the relationship between chemical modification and measured peptide persistence.

Laboratory research topics

In vitro peptide-degradation comparisons in defined plasma systems.
Chemical-modification and immunoreactive-peptide measurements.

Evidence in context

Original nonclinical pharmacology study

Plasma degradation and immunoreactive-peptide measurements are method- and species-dependent. Persistence measurements do not establish a general biological effect; the paper also reports adverse findings in repeat-exposure animal experiments.

Published studies describe their own experimental models and preparations. They do not establish the identity, quality, or suitability of an EliteGen batch for a particular experiment.

References 1